Active Articulation™ Dual Mobility Hip System

Dislocation is second to infection as the main early complication following THA.1 Dual mobility constructs have demonstrated long-term clinical success in Europe reducing risk of dislocation1-6,12 The Active Articulation™ E1® Hip System defines the next generation of dual mobility constructs as it is specifically indicated for patients at risk for dislocation8 and the only dual mobility system to utilize Antioxidant Infused Technology.

  • Dislocation Resistance 
  • Ultra-Low Wear - 95% less wear than traditional THA, even when cup is at 60º inclination7
  • Large Range of Motion - Provides up to 165 degrees7
  • Oxidative Stability - E1® Antioxidant Infused Technology prevents oxidative degradation of polyethylene.9
  • Clinically Proven Cup10 - The fully-hemispheric M2a-Magnum™ cup contains clinically proven PPS® coating11 and fins to provide fixation and stability

References

  1. Farizon, F. et al. Results with a cementless alumina-coated cup with dual mobility. A twelve-year follow-up study. International Orthopaedics. 22(2):219-24, 1998
  2. Langlais, F.L. et al. Dual mobility cemented cups have low dislo¬cation rates in THA revisions. Clinical Orthopaedics and Related Research. 466:389-95, 2008.
  3. Philippot, R. et al. The use of a dual-articulation acetabular cup system to prevent dislocation after primary total hip arthroplasty: analysis of 384 cases at a mean follow-up of 15 years. International Orthopaedics. 33:927-32, 2009.
  4. Guyen, O. et al. Use of a dual mobility socket to manage total hip arthropalsty instability. Clinical Orthopaedics and Related Research. 467:465-72, 2009.
  5. Philippot, R. et al. Prevention of dislocation in total hip revision sur¬gery using a dual mobility design. Orthopaedics and Traumatolology: Surgery and Research. 95:407-13, 2009.
  6. Massin, P, Besnier L, Acetabular revision of total hip arthroplasty using a press-fit dual mobility cup. Orthopaedics and Traumatology: Surgery and Research. 96:9-13, 2010.
  7. Data on file at Biomet. Bench test results not necessarily indicative of clinical performance.
  8. See biomet.com for package insert.
  9. FDA Cleared Claim. See biomet.com/e1 for complete claim language.
  10. Ongoing, multi-center study demonstrated 99.6% survivorship at 2.5 yeas. Data on file at Biomet.
  11. McLaughlin, J.R. and Lee, K.R. Survivorship at 22 to 26 Years Reported with Uncemented Tapered Total Hip Stem. Orthopedics Today. 30(1): 1, 2010.
  12. Fresard, P., et al. Seven-year results of a press-fit, hydroxyapatite-coated double mobility acetabular component in patients aged 65 years or older. European Journal of Orthopaedic Surgery Traumatology. Volume 20, Number 5, July 2010.

All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.  
This material is intended for health care professionals. Distribution to any other recipient is prohibited.
For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert and information on this website. To obtain a copy of the current Instructions for Use (IFU) for full prescribing and risk information, please call 1-800-348-2759, press 4 for 411 Technical Support.